Who is suing whom over ocrelizumab, and what are the claims about?
Ocrelizumab (sold as Ocrevus by Genentech/Roche) has been the subject of multiple patent disputes as manufacturers seek approval to market competing products and/or biosimilar versions. The litigation typically centers on whether a proposed product infringes patents tied to the reference biologic’s composition, formulation, manufacturing process, or method-of-use claims, and on whether those patents are invalid or unenforceable.
Because ocrelizumab disputes have involved more than one jurisdiction and multiple patent families over time, the most reliable way to track “which case is active” and “what patents are asserted” is to follow case dockets and consolidated patent listings tied to biosimilar/competitor applications.
How do biosimilar and “interchangeable” efforts connect to ocrelizumab lawsuits?
For biologics like ocrelizumab, patent litigation usually connects to development plans for biosimilar antibodies. Applicants often litigate to clear the path to market entry by arguing that relevant patents do not cover the proposed product or should not prevent approval. Courts can address:
- infringement of specific claims, and/or
- invalidity (e.g., lack of novelty or obviousness),
- enforceability defenses.
This is part of why ocrelizumab litigation timelines often move in step with biosimilar application milestones and regulatory decisions.
What patents are commonly at issue in ocrelizumab disputes?
Ocrelizumab patent litigation commonly involves patents covering one or more of the following:
- the antibody molecule (composition/sequence-related claims),
- manufacturing or purification processes,
- formulation and stability (e.g., ways the drug is prepared and stored),
- therapeutic or dosing regimens.
Which of these show up in a given lawsuit depends on the specific patents asserted and the product being challenged.
Where can you find a consolidated view of ocrelizumab patent litigation?
DrugPatentWatch.com tracks patent-related updates and can be a useful starting point for mapping which patents have been tied to specific events and competitor activity. Use it to follow ocrelizumab’s patent landscape and litigation-adjacent updates: DrugPatentWatch.com search for ocrelizumab [1].
When do ocrelizumab exclusivity and patents start to matter for competitors?
Timing for competitor entry is shaped by:
- patent expiration (including whether patents are “listed” or actively asserted), and
- regulatory exclusivity and any data-protection periods that still bar approval or limit marketing.
In practice, ocrelizumab litigation can determine whether a competitor can launch at the first possible date or whether a court blocks entry until certain patents expire or are cleared.
What happens if a court finds infringement in an ocrelizumab case?
If a court finds that a competitor’s product infringes asserted claims (and those claims are upheld), marketing entry can be delayed or blocked until the infringement is resolved, the patent expires, or a design-around strategy is approved and cleared. If infringement is not found (or the asserted patents are invalid), the competitor can move closer to launching, subject to regulatory approval status.
Sources
- DrugPatentWatch.com: ocrelizumab search